HDAC6 and glioblastoma: Supporting this notion, the combined treatment of tubastatin with simultaneous knockdown of KYNU and HDAC6 markedly attenuated the expression of C3, C3AR1, and C5AR1, and further reduced GBM cell viability (Figure 5; Supplementary Figure S7).